Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18277722 | 1.00 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL8214230 | 0.84 | FPR2 (0.66) | FPR2FOLH1 | |
| SCHEMBL9618591 | 0.83 | GAA (0.73) | SMN1; SMN2HSD17B10GAAMAPT | |
| SCHEMBL9618589 | 0.83 | GAA (0.73) | SMN1; SMN2HSD17B10GAAMAPT | |
| SCHEMBL9333451 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL11418240 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL9333446 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL8088674 | 0.83 | FPR2 (0.56) | FPR2TP53EPHX1TSHREPHX2 | |
| SCHEMBL6375756 | 0.81 | FPR2 (0.81) | FPR2FOLH1 | |
| SCHEMBL6381444 | 0.81 | FPR2 (0.81) | FPR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0511558-B1 | Process for the resolution of racemates and associates of diastereoisomers | HOFFMANN LA ROCHE (CH) | 1996-10-23 | — | — | EP | claimed |
| US-5334766-A | Process for the resolution of racemic diphosphine oxides | HOFFMANN-LA ROCHE INC. (US) | 1994-08-02 | — | — | US | claimed |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-13 | — | — | US | disclosed |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-08 | — | — | US | disclosed |
| US-5334766-A | Process for the resolution of racemic diphosphine oxides | HOFFMANN-LA ROCHE INC. (US) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | GOT2, GOT1, OTC | FPR2 4619/4885TP53 588/4885EPHX1 2033/4885 |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | GOT2, GOT1, OTC | FPR2 4619/4885TP53 588/4885EPHX1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.